Avanafil metabolite M16 | CAS#2748151-94-0 | Inactive metabolite

MedKoo Cat#: 574225 | Name: Avanafil metabolite M16

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Avanafil metabolite M16 is a major inactive metabolite of the phosphodiesterase 5 (PDE5) inhibitor avanafil. Avanafil is metabolized by the cytochrome P450 (CYP450) isoforms CYP3A4 and CYP2C to the major metabolites avanafil metabolite M16 and avanafil metabolite M4 as well as minor metabolites.

Chemical Structure

Avanafil metabolite M16

CAS#2748151-94-0 (metabolite M16)

Theoretical Analysis

MedKoo Cat#: 574225

Name: Avanafil metabolite M16

CAS#: 2748151-94-0 (metabolite M16)

Chemical Formula: C23H26ClN7O5

Exact Mass: 515.1684

Molecular Weight: 515.96

Elemental Analysis: C, 53.54; H, 5.08; Cl, 6.87; N, 19.00; O, 15.50

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 950.00	Back order

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

330784-47-9 (free base) 330784-48-0 (dibesylate) Avanafil metabolite M4 2748151-94-0 (metabolite M16)

Synonym

Avanafil metabolite M16

IUPAC/Chemical Name

4-((4-((3-chloro-4-methoxybenzyl)amino)-5-((pyrimidin-2-ylmethyl)carbamoyl)pyrimidin-2-yl)amino)-5-hydroxypentanoic acid

InChi Key

PRFBRQCNRFBCHL-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H26ClN7O5/c1-36-18-5-3-14(9-17(18)24)10-27-21-16(22(35)28-12-19-25-7-2-8-26-19)11-29-23(31-21)30-15(13-32)4-6-20(33)34/h2-3,5,7-9,11,15,32H,4,6,10,12-13H2,1H3,(H,28,35)(H,33,34)(H2,27,29,30,31)

SMILES Code

COC1=CC=C(CNC2=NC(NC(CO)CCC(O)=O)=NC=C2C(NCC3=NC=CC=N3)=O)C=C1Cl

Appearance

Solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 515.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Avanafil. 2017 Aug 2. PMID: 31643479. 2: Avanafil for erectile dysfunction. Aust Prescr. 2019 Jun;42(3):113-114. doi: 10.18773/austprescr.2019.043. Epub 2019 May 13. PMID: 31363316; PMCID: PMC6594841. 3: Kyle JA, Brown DA, Hill JK. Avanafil for erectile dysfunction. Ann Pharmacother. 2013 Oct;47(10):1312-20. doi: 10.1177/1060028013501989. Epub 2013 Sep 27. PMID: 24259695. 4: Boeri L, Capogrosso P, Ventimiglia E, Serino A, La Croce G, Russo A, Damiano R, Montorsi F, Salonia A. Avanafil - a further step to tailoring patient needs and expectations. Expert Rev Clin Pharmacol. 2016 Sep;9(9):1171-81. doi: 10.1080/17512433.2016.1195261. Epub 2016 Jun 13. PMID: 27232892. 5: Sanford M. Avanafil: a review of its use in patients with erectile dysfunction. Drugs Aging. 2013 Oct;30(10):853-62. doi: 10.1007/s40266-013-0112-x. PMID: 23955441. 6: Zurawin JL, Stewart CA, Anaissie JE, Yafi FA, Hellstrom WJ. Avanafil for the treatment of erectile dysfunction. Expert Rev Clin Pharmacol. 2016 Sep;9(9):1163-70. doi: 10.1080/17512433.2016.1212655. Epub 2016 Aug 2. PMID: 27416913. 7: Burke RM, Evans JD. Avanafil for treatment of erectile dysfunction: review of its potential. Vasc Health Risk Manag. 2012;8:517-23. doi: 10.2147/VHRM.S26712. Epub 2012 Aug 29. PMID: 22973106; PMCID: PMC3433322. 8: Egui-Rojo MA, Moncada-Iribarren I, Carballido-Rodríguez J, Martínez-Salamanca JI. Avanafil for the treatment of erectile dysfunction. An updated review. Arch Esp Urol. 2014 Dec;67(10):839-47. English, Spanish. PMID: 25582903. 9: Cui YS, Li N, Zong HT, Yan HL, Zhang Y. Avanafil for male erectile dysfunction: a systematic review and meta-analysis. Asian J Androl. 2014 May- Jun;16(3):472-7. doi: 10.4103/1008-682X.123670. PMID: 24589460; PMCID: PMC4023381. 10: Kumar M, Pathade AD, Gupta SV, Goyal S, Rath D, Thakre M, Sanmukhani J, Mittal R. Efficacy and safety of avanafil as compared with sildenafil in the treatment of erectile dysfunction: A randomized, double blind, multicenter clinical trial. Int J Urol. 2022 Apr;29(4):351-359. doi: 10.1111/iju.14785. Epub 2022 Jan 26. PMID: 35080051; PMCID: PMC9303470. 11: Segal R, Burnett AL. Avanafil for the treatment of erectile dysfunction. Drugs Today (Barc). 2012 Jan;48(1):7-15. doi: 10.1358/dot.2012.48.1.1722068. PMID: 22384456. 12: Derosa G, D'Angelo A, Preti PS, Maffioli P. Evaluation of the Effect on Sexual Performance of a Nutraceutical Combination Containing Alpha Lipoic Acid, Vitis vinifera L. and Ginkgo biloba, Compared to Placebo, Avanafil or a Combination of Nutraceutical Plus Avanafil in Males With Type 2 Diabetes Mellitus With Erectile Dysfunction. Front Endocrinol (Lausanne). 2022 Apr 7;13:847240. doi: 10.3389/fendo.2022.847240. PMID: 35464055; PMCID: PMC9022207. 13: Limin M, Johnsen N, Hellstrom WJ. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opin Investig Drugs. 2010 Nov;19(11):1427-37. doi: 10.1517/13543784.2010.518955. Epub 2010 Oct 13. PMID: 20939743. 14: Corona G, Rastrelli G, Burri A, Jannini EA, Maggi M. The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta- analysis. Expert Opin Drug Saf. 2016;15(2):237-47. doi: 10.1517/14740338.2016.1130126. Epub 2016 Jan 20. Erratum in: Expert Opin Drug Saf. 2016;15(2):v. PMID: 26646748. 15: Dhruva A, Hamsavardhini VK, Kamatham S, Kataria A, Kumar A, Shanthi M, Peedicayil J. Avanafil Inhibits the Contractility of the Isolated Caprine Detrusor Muscle. Int J Appl Basic Med Res. 2019 Oct-Dec;9(4):231-235. doi: 10.4103/ijabmr.IJABMR_339_18. Epub 2019 Oct 11. PMID: 31681549; PMCID: PMC6822320. 16: Wang H, Yuan J, Hu X, Tao K, Liu J, Hu D. The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis. Curr Med Res Opin. 2014 Aug;30(8):1565-71. doi: 10.1185/03007995.2014.909391. Epub 2014 Apr 14. PMID: 24701971. 17: Katz EG, Tan RB, Rittenberg D, Hellstrom WJ. Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility. Ther Clin Risk Manag. 2014 Aug 27;10:701-11. doi: 10.2147/TCRM.S57610. PMID: 25210457; PMCID: PMC4155803. 18: Kotera J, Mochida H, Inoue H, Noto T, Fujishige K, Sasaki T, Kobayashi T, Kojima K, Yee S, Yamada Y, Kikkawa K, Omori K. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol. 2012 Aug;188(2):668-74. doi: 10.1016/j.juro.2012.03.115. Epub 2012 Jun 15. PMID: 22704456. 19: Chowdari Gurram P, Satarker S, Kumar G, Begum F, Mehta C, Nayak U, Mudgal J, Arora D, Nampoothiri M. Avanafil mediated dual inhibition of IKKβ and TNFR1 in an experimental paradigm of Alzheimer's disease: in silico and in vivo approach. J Biomol Struct Dyn. 2022 Dec 19:1-19. doi: 10.1080/07391102.2022.2156924. Epub ahead of print. PMID: 36533331. 20: Aydin P, Magden ZBA, Uzuncakmak SK, Halici H, Akgun N, Mendil AS, Mokhtare B, Cadirci E. Avanafil as a Novel Therapeutic Agent Against LPS-Induced Acute Lung Injury via Increasing CGMP to Downregulate the TLR4-NF-κB-NLRP3 Inflammasome Signaling Pathway. Lung. 2022 Oct;200(5):561-572. doi: 10.1007/s00408-022-00564-9. Epub 2022 Aug 30. PMID: 36040529.